Martin Johansson
Directeur Général chez Glactone Pharma AB
Postes actifs de Martin Johansson
Sociétés | Poste | Début | Fin |
---|---|---|---|
University of Lund | Corporate Officer/Principal | - | - |
Glactone Pharma AB
Glactone Pharma AB Pharmaceuticals: MajorHealth Technology Glactone Pharma AB engages in the development of pipeline of novel signal transducer and activator of transcription 3 inhibitors. Its pipeline is used for immuno-oncology and for the treatment of drug resistant cancers, including castration resistant prostate cancer. The company was founded by Anders Sigvard Bjartell, Rebecka Hellsten, Martin Johansson, Eduardo Munoz, and Olov Arvid Sterner in 2012 and is headquartered in Helsingborg, Sweden. | Directeur Général | 01/01/2012 | - |
Fondateur | 01/01/2012 | - |
Historique de carrière de Martin Johansson
Anciens postes connus de Martin Johansson
Sociétés | Poste | Début | Fin |
---|---|---|---|
Respiratorius AB
Respiratorius AB Pharmaceuticals: MajorHealth Technology Respiratorius AB engages in the development of drug candidates for Chronic Obstructive Pulmonary Disease, asthma, and cancer. The company was founded by Lars Christer Fedrik Fåhraeus and Staffan Skogwall in 1999 and is headquartered in Lund, Sweden. | Directeur Technique/Scientifique/R&D | 01/01/2006 | - |
Corporate Officer/Principal | - | 01/01/2011 |
Statistiques
Internationale
Suède | 4 |
Opérationnelle
Corporate Officer/Principal | 2 |
Chief Tech/Sci/R&D Officer | 1 |
Chief Executive Officer | 1 |
Sectorielle
Health Technology | 3 |
Consumer Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 1 |
---|---|
Health Technology |
Entreprise privées | 1 |
---|---|
Glactone Pharma AB
Glactone Pharma AB Pharmaceuticals: MajorHealth Technology Glactone Pharma AB engages in the development of pipeline of novel signal transducer and activator of transcription 3 inhibitors. Its pipeline is used for immuno-oncology and for the treatment of drug resistant cancers, including castration resistant prostate cancer. The company was founded by Anders Sigvard Bjartell, Rebecka Hellsten, Martin Johansson, Eduardo Munoz, and Olov Arvid Sterner in 2012 and is headquartered in Helsingborg, Sweden. | Health Technology |
- Bourse
- Insiders
- Martin Johansson
- Expérience